Sun Pharma, one of India’s leading pharmaceutical companies, has announced its plans to expand its specialty business through strategic licensing and mergers and acquisitions (M&A). The Mumbai-based firm is keen on developing an internal product pipeline and has previously grown its specialty business through a series of strategic agreements. The upcoming delisting and merger of Taro Pharmaceuticals will further support Sun Pharma’s growth initiatives.

Pharmaceuticals, Healthcare, Mergers & Acquisitions (M&A),India, Global

https://mergersacquisitions.einnews.com/article/714951824/RyTl2Quelz6hg97w?ref=rss&ecode=Q1vNcweEggLWKz7L